Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases

Microsomal prostaglandin E synthase-1 (mPGES-1) is a well-recognized target for the development of novel anti-inflammatory drugs that can reduce symptoms of inflammation in rheumatic diseases and other inflammatory conditions. In this review, we focus on mPGES-1 in rheumatic diseases with the aim to...

Descripción completa

Detalles Bibliográficos
Autores principales: Korotkova, Marina, Jakobsson, Per-Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174088/
https://www.ncbi.nlm.nih.gov/pubmed/21927605
http://dx.doi.org/10.3389/fphar.2010.00146
_version_ 1782212026513227776
author Korotkova, Marina
Jakobsson, Per-Johan
author_facet Korotkova, Marina
Jakobsson, Per-Johan
author_sort Korotkova, Marina
collection PubMed
description Microsomal prostaglandin E synthase-1 (mPGES-1) is a well-recognized target for the development of novel anti-inflammatory drugs that can reduce symptoms of inflammation in rheumatic diseases and other inflammatory conditions. In this review, we focus on mPGES-1 in rheumatic diseases with the aim to cover the most recent advances in the understanding of mPGES-1 in rheumatoid arthritis, osteoarthritis, and inflammatory myopathies. Novel findings regarding regulation of mPGES-1 cell expression as well as enzyme inhibitors are also summarized.
format Online
Article
Text
id pubmed-3174088
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-31740882011-09-16 Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases Korotkova, Marina Jakobsson, Per-Johan Front Pharmacol Pharmacology Microsomal prostaglandin E synthase-1 (mPGES-1) is a well-recognized target for the development of novel anti-inflammatory drugs that can reduce symptoms of inflammation in rheumatic diseases and other inflammatory conditions. In this review, we focus on mPGES-1 in rheumatic diseases with the aim to cover the most recent advances in the understanding of mPGES-1 in rheumatoid arthritis, osteoarthritis, and inflammatory myopathies. Novel findings regarding regulation of mPGES-1 cell expression as well as enzyme inhibitors are also summarized. Frontiers Research Foundation 2011-01-20 /pmc/articles/PMC3174088/ /pubmed/21927605 http://dx.doi.org/10.3389/fphar.2010.00146 Text en Copyright © 2011 Korotkova and Jakobsson. http://www.frontiersin.org/licenseagreement This is an open-access article subject to an exclusive license agreement between the authors and Frontiers Media SA, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
spellingShingle Pharmacology
Korotkova, Marina
Jakobsson, Per-Johan
Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title_full Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title_fullStr Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title_full_unstemmed Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title_short Microsomal Prostaglandin E Synthase-1 in Rheumatic Diseases
title_sort microsomal prostaglandin e synthase-1 in rheumatic diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174088/
https://www.ncbi.nlm.nih.gov/pubmed/21927605
http://dx.doi.org/10.3389/fphar.2010.00146
work_keys_str_mv AT korotkovamarina microsomalprostaglandinesynthase1inrheumaticdiseases
AT jakobssonperjohan microsomalprostaglandinesynthase1inrheumaticdiseases

Ejemplares similares